HUP0001562A2 - Amino-triazol-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények - Google Patents
Amino-triazol-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítményekInfo
- Publication number
- HUP0001562A2 HUP0001562A2 HU0001562A HUP0001562A HUP0001562A2 HU P0001562 A2 HUP0001562 A2 HU P0001562A2 HU 0001562 A HU0001562 A HU 0001562A HU P0001562 A HUP0001562 A HU P0001562A HU P0001562 A2 HUP0001562 A2 HU P0001562A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- heteroaryl
- aryl
- aralkyl
- general formula
- Prior art date
Links
- JSIAIROWMJGMQZ-UHFFFAOYSA-N 2h-triazol-4-amine Chemical class NC1=CNN=N1 JSIAIROWMJGMQZ-UHFFFAOYSA-N 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 125000005015 aryl alkynyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 3
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 2
- 125000005312 heteroarylalkynyl group Chemical group 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 208000000103 Anorexia Nervosa Diseases 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010006550 Bulimia nervosa Diseases 0.000 abstract 1
- 101710151321 Melanostatin Proteins 0.000 abstract 1
- 102400000064 Neuropeptide Y Human genes 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000037849 arterial hypertension Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 125000005549 heteroarylene group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- BPGXUIVWLQTVLZ-OFGSCBOVSA-N neuropeptide y(npy) Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 BPGXUIVWLQTVLZ-OFGSCBOVSA-N 0.000 abstract 1
- 208000019180 nutritional disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004584 weight gain Effects 0.000 abstract 1
- 235000019786 weight gain Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/14—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
A találmány az (I) általános képletű vegyületekre, enantiomerjeikre,diasztereoizomerjeikre, valamint e vegyületek gyógyászati szempontbólelfogadható savakkal vagy bázisokkal alkotott addíciós sóiravonatkozik. A találmány szerinti vegyületek (I) képletében n értéke 0 vagy 1 , W jelentése -CO- vagy S(O)q általános képletű csoport, amelyben qértéke 0, 1 vagy 2; G jelentése (G1), (G2), (G3) vagy (G4) általános képletű csoport; Z jelentése alkil-, aril-, heteroaril-; aralkil-, aril-aIkenil-, aril-alkinil-, heteroaril-alkenil-, heteroaril-alkinil- vagy hetero-aralkilcsoport, amelyek adott esetben szubsztituáltak is lehetnek; A jelentése -A2-, -A1-A2-, -A2-A1- és -A1-A2-A1- általános képletűcsoport, amelyben A1 jelentése alkiléncsoport, és A2 jelentése adottesetben szubsztituált fenilén-, cikloalkilén-naftilén- vagyheteroariléncsoport; R jelentése hidrogénatom, alkil-, aril-, heteroaril-, aralkil-, aril-alkenil-, aril-alkinil-, heteroaril-alkenil- vagy heteroaril-alkinil-vagy heteroaralkilcsoport, amelyek adott esetben szubsztituáltak islehetnek; R1 jelentése alkil-, aril-, heteroaril-, aralkil-, aril-alkenil-,aril-alkinil-, heteroaril-alkenil-, heteroaril-aIkinil- vagy hetero-aralkilcsoport, amelyek szubsztituáltak is lehetnek. A találmányszerinti hatásos vegyületek az Y neuro-peptiddel (NPY) kapcsolatoskóros állapotok kezelésére alkalmazhatók. Ennek következtében gátoljáka táplálékfelvételt és a súlyszaporulatot, mivel az NPY-receptorokhozkötődnek. Terápiásan alkalmazhatók táplálkozási betegségek, példáulcukorbetegség, elhízás, bulimia és ideges étvágytalanság kezelésére,valamint figyelembe vehetők artériás magas vérnyomás; szorongás,depresszió kezeléséré is. Ó
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9904721A FR2792314B1 (fr) | 1999-04-15 | 1999-04-15 | Nouveaux composes aminotriazoles, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HU0001562D0 HU0001562D0 (en) | 2000-06-28 |
| HUP0001562A2 true HUP0001562A2 (hu) | 2001-04-28 |
| HUP0001562A3 HUP0001562A3 (en) | 2003-05-28 |
Family
ID=9544433
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0001562A HUP0001562A3 (en) | 1999-04-15 | 2000-04-14 | Aminotriazole derivatives process for their preparation and medicaments containing the same |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US6245916B1 (hu) |
| EP (1) | EP1044970B1 (hu) |
| JP (1) | JP2000309579A (hu) |
| KR (1) | KR20010020732A (hu) |
| CN (1) | CN1145616C (hu) |
| AT (1) | ATE231133T1 (hu) |
| BR (1) | BR0001602A (hu) |
| CA (1) | CA2305940A1 (hu) |
| DE (1) | DE60001190T2 (hu) |
| DK (1) | DK1044970T3 (hu) |
| EA (1) | EA003023B1 (hu) |
| ES (1) | ES2190396T3 (hu) |
| FR (1) | FR2792314B1 (hu) |
| HU (1) | HUP0001562A3 (hu) |
| NO (1) | NO20001964L (hu) |
| NZ (1) | NZ504023A (hu) |
| PL (1) | PL339690A1 (hu) |
| SI (1) | SI1044970T1 (hu) |
| ZA (1) | ZA200001908B (hu) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050020547A1 (en) * | 1999-11-08 | 2005-01-27 | Pfizer Inc. | Compounds for the treatment of female sexual dysfunction |
| EP1381360A4 (en) * | 2001-03-29 | 2009-12-02 | Smithkline Beecham Corp | COMPOUNDS AND METHODS FOR INHIBITING METAP2 IN MAMMALS |
| MXPA02010231A (es) | 2001-11-27 | 2004-12-13 | Warner Lambert Co | Inhibidores aminotransferasa dependientes de aminoacidos de cadena ramificada y su uso en el tratamiento de las enfermedades neurodegenerativas. |
| US20050119251A1 (en) * | 2001-12-21 | 2005-06-02 | Jian-Min Fu | Nicotinamide derivatives and their use as therapeutic agents |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| US20050282814A1 (en) * | 2002-10-03 | 2005-12-22 | Targegen, Inc. | Vasculostatic agents and methods of use thereof |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| AU2005231507B2 (en) | 2004-04-08 | 2012-03-01 | Targegen, Inc. | Benzotriazine inhibitors of kinases |
| WO2006024034A1 (en) * | 2004-08-25 | 2006-03-02 | Targegen, Inc. | Heterocyclic compounds and methods of use |
| JP5080256B2 (ja) * | 2004-09-20 | 2012-11-21 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 二環式複素環誘導体およびステアロイル−ＣｏＡデサチュラーゼ（ＳＣＤ）のインヒビターとしてのそれらの使用 |
| TW200626154A (en) | 2004-09-20 | 2006-08-01 | Xenon Pharmaceuticals Inc | Heterocyclic derivatives and their use as therapeutic agents |
| MX2007003332A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa. |
| EP1804799B1 (en) * | 2004-09-20 | 2013-08-21 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors |
| JP5149009B2 (ja) | 2004-09-20 | 2013-02-20 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | ヒトステアロイル−ＣｏＡデサチュラーゼを阻害するためのピリダジン誘導体 |
| DE602005025924D1 (en) * | 2004-09-20 | 2011-02-24 | Xenon Pharmaceuticals Inc | Royl-coa-desaturase |
| MX2007003327A (es) * | 2004-09-20 | 2007-06-05 | Xenon Pharmaceuticals Inc | Derivados heterociclicos, y su uso como mediadores de estearoil-coa desaturasa. |
| BRPI0515483A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos para o tratamento de doenças mediadas por enzimas estearoil-coa desaturase |
| JP5043668B2 (ja) * | 2004-09-20 | 2012-10-10 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 複素環誘導体および治療薬としてのそれらの使用 |
| BRPI0518241A (pt) | 2004-11-01 | 2008-04-22 | Amylin Pharmaceuticals Inc | métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| BRPI0610580B8 (pt) | 2005-05-30 | 2021-05-25 | Banyu Pharma Co Ltd | composto derivado de piperidina |
| MX2007015216A (es) * | 2005-06-03 | 2008-02-22 | Xenon Pharmaceuticals Inc | Derivados de aminotiazol y sus usos como agentes terapeuticos. |
| AU2006277253A1 (en) | 2005-08-10 | 2007-02-15 | Msd K.K. | Pyridone compound |
| AU2006282260A1 (en) | 2005-08-24 | 2007-03-01 | Msd K.K. | Phenylpyridone derivative |
| JPWO2007029847A1 (ja) | 2005-09-07 | 2009-03-19 | 萬有製薬株式会社 | 二環性芳香族置換ピリドン誘導体 |
| AU2006297443B2 (en) | 2005-09-29 | 2010-08-12 | Merck Sharp & Dohme Corp. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| WO2007049798A1 (ja) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | 新規ベンゾオキサチイン誘導体 |
| NZ568292A (en) | 2005-11-10 | 2011-08-26 | Msd Kk | Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives |
| MX2008009215A (es) * | 2006-01-17 | 2008-12-10 | Barrier Therapeutics Inc | Tratamiento de trastornos inflamatorios con compuestos de triazol. |
| JO3019B1 (ar) | 2006-04-19 | 2016-09-05 | Janssen Pharmaceutica Nv | ثلاثي مستبدل 4،2،1-ثلاثي زولات |
| EP2083831B1 (en) | 2006-09-22 | 2013-12-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
| JPWO2008038692A1 (ja) | 2006-09-28 | 2010-01-28 | 萬有製薬株式会社 | ジアリールケチミン誘導体 |
| AU2008233662B2 (en) | 2007-04-02 | 2012-08-23 | Msd K.K. | Indoledione derivative |
| EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| JO2784B1 (en) * | 2007-10-18 | 2014-03-15 | شركة جانسين فارماسوتيكا ان. في | 5,3,1 - Triazole substitute derivative |
| US8440701B2 (en) | 2007-10-18 | 2013-05-14 | Janssen Pharmaceutica Nv | Trisubstituted 1,2,4 triazoles |
| CN101939022A (zh) * | 2007-11-14 | 2011-01-05 | 安米林药品公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| AU2009220605A1 (en) | 2008-03-06 | 2009-09-11 | Msd K.K. | Alkylaminopyridine derivative |
| NZ587669A (en) * | 2008-03-19 | 2011-07-29 | Janssen Pharmaceutica Nv | Trisubstituted 1, 2, 4 -triazoles as nicotinic acetylcholine receptor modulators |
| AU2009229860A1 (en) | 2008-03-28 | 2009-10-01 | Msd K.K. | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
| BRPI0912196A2 (pt) * | 2008-05-09 | 2015-10-06 | Janssen Pharmaceutica Nv | pirazóis trissubstituídos como moduladores do receptor de acetilcolina. |
| TWI490214B (zh) * | 2008-05-30 | 2015-07-01 | 艾德克 上野股份有限公司 | 苯或噻吩衍生物及該等作為ｖａｐ－１抑制劑之用途 |
| EP2810951B1 (en) | 2008-06-04 | 2017-03-15 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| JPWO2010013595A1 (ja) | 2008-07-30 | 2012-01-12 | Ｍｓｄ株式会社 | ５員−５員又は５員−６員縮環シクロアルキルアミン誘導体 |
| WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| CA2741672A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US8775245B2 (en) | 2010-02-11 | 2014-07-08 | News America Marketing Properties, Llc | Secure coupon distribution |
| AU2011218830B2 (en) | 2010-02-25 | 2014-07-24 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| EP2623499B1 (en) * | 2010-10-01 | 2015-04-22 | Taisho Pharmaceutical Co., Ltd | 1,2,4-triazolone derivative |
| EP3243385B1 (en) | 2011-02-25 | 2021-01-13 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
| JP2015525782A (ja) | 2012-08-02 | 2015-09-07 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病性三環式化合物 |
| CA2905438A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PT3004138T (pt) | 2013-06-05 | 2024-06-18 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclase c, método de produção e utilização dos mesmos |
| CA2959208C (en) | 2014-08-29 | 2023-09-19 | Tes Pharma S.R.L. | Pyrimidine derivatives and their use as inhibitors of alpha-amino-beta-carboxymuconate-epsilon-semialdehyde decarboxylase |
| EP3526199B1 (en) | 2016-10-14 | 2022-04-13 | Tes Pharma S.r.l. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
| CA3119509A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxxylase |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4326465A1 (de) * | 1993-01-20 | 1995-02-09 | Thomae Gmbh Dr K | Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| WO1997036859A1 (en) * | 1996-03-29 | 1997-10-09 | G.D. Searle & Co. | Para-substituted phenylpropanoic acid derivatives as integrin antagonists |
| US6180653B1 (en) * | 1996-12-16 | 2001-01-30 | Banyu Pharmaceutical Co., Ltd. | Aminopyrazole derivatives |
| PE20000127A1 (es) * | 1997-12-22 | 2000-03-14 | Novartis Ag | Derivado de bencenosulfonamida |
-
1999
- 1999-04-15 FR FR9904721A patent/FR2792314B1/fr not_active Expired - Fee Related
-
2000
- 2000-04-12 KR KR1020000019224A patent/KR20010020732A/ko active IP Right Grant
- 2000-04-13 BR BR0001602-0A patent/BR0001602A/pt not_active IP Right Cessation
- 2000-04-14 NO NO20001964A patent/NO20001964L/no not_active Application Discontinuation
- 2000-04-14 CA CA002305940A patent/CA2305940A1/fr not_active Abandoned
- 2000-04-14 DE DE60001190T patent/DE60001190T2/de not_active Expired - Fee Related
- 2000-04-14 CN CNB001065793A patent/CN1145616C/zh not_active Expired - Fee Related
- 2000-04-14 ZA ZA200001908A patent/ZA200001908B/xx unknown
- 2000-04-14 JP JP2000113113A patent/JP2000309579A/ja active Pending
- 2000-04-14 PL PL00339690A patent/PL339690A1/xx not_active Application Discontinuation
- 2000-04-14 DK DK00401039T patent/DK1044970T3/da active
- 2000-04-14 AT AT00401039T patent/ATE231133T1/de not_active IP Right Cessation
- 2000-04-14 ES ES00401039T patent/ES2190396T3/es not_active Expired - Lifetime
- 2000-04-14 HU HU0001562A patent/HUP0001562A3/hu unknown
- 2000-04-14 EP EP00401039A patent/EP1044970B1/fr not_active Expired - Lifetime
- 2000-04-14 NZ NZ504023A patent/NZ504023A/xx unknown
- 2000-04-14 US US09/549,745 patent/US6245916B1/en not_active Expired - Fee Related
- 2000-04-14 EA EA200000327A patent/EA003023B1/ru not_active IP Right Cessation
- 2000-04-14 SI SI200030042T patent/SI1044970T1/xx unknown
-
2001
- 2001-03-05 US US09/799,199 patent/US6596749B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| FR2792314A1 (fr) | 2000-10-20 |
| DE60001190D1 (de) | 2003-02-20 |
| CN1145616C (zh) | 2004-04-14 |
| ATE231133T1 (de) | 2003-02-15 |
| NZ504023A (en) | 2000-10-27 |
| DE60001190T2 (de) | 2003-10-09 |
| NO20001964D0 (no) | 2000-04-14 |
| JP2000309579A (ja) | 2000-11-07 |
| US6596749B2 (en) | 2003-07-22 |
| KR20010020732A (ko) | 2001-03-15 |
| EA200000327A2 (ru) | 2000-10-30 |
| EA003023B1 (ru) | 2002-12-26 |
| BR0001602A (pt) | 2001-08-21 |
| CA2305940A1 (fr) | 2000-10-15 |
| US20010018522A1 (en) | 2001-08-30 |
| DK1044970T3 (da) | 2003-04-22 |
| CN1272493A (zh) | 2000-11-08 |
| HU0001562D0 (en) | 2000-06-28 |
| HUP0001562A3 (en) | 2003-05-28 |
| EP1044970A1 (fr) | 2000-10-18 |
| PL339690A1 (en) | 2000-10-23 |
| SI1044970T1 (en) | 2003-06-30 |
| ZA200001908B (en) | 2000-10-31 |
| EP1044970B1 (fr) | 2003-01-15 |
| NO20001964L (no) | 2000-10-16 |
| US6245916B1 (en) | 2001-06-12 |
| ES2190396T3 (es) | 2003-08-01 |
| FR2792314B1 (fr) | 2001-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0001562A2 (hu) | Amino-triazol-származékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyászati készítmények | |
| US4048317A (en) | Chroman derivatives | |
| DE69503803D1 (de) | 3,5-dioxo-(2h,4h)-1,2,4-triazinderivate ihre herstellung und verwendung als medikament | |
| MXPA04009784A (es) | Tiazolidin-4-carbonitrilos y analogos y su uso como inhibidores de dipeptidil-peptidas. | |
| RU2002107975A (ru) | Глюкопиранозилоксипиразольные производные, лекарственные композиции, содержащие эти производные, и промежуточные соединения для их получения | |
| NZ545692A (en) | PPAR-activating compound and pharmaceutical composition containing same | |
| KR950008512A (ko) | 이미다조피리딘 유도체의 제조방법 | |
| ATE338754T1 (de) | Heterocyclische verbindungen, ihre herstellung und verwendung | |
| DE50011034D1 (de) | N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel | |
| EP1394154A4 (en) | HETEROCYCLIC DERIVATIVE WITH FIVE MEMBERS OF ALKANOIC ACID | |
| ATE146169T1 (de) | Dihydropyridin-derivate, ihre herstellung und ihre anwendung | |
| DE60009777D1 (de) | Verbindungen zur Behandlung und Vorsorge bei Diabetes | |
| HU196413B (en) | Process for production of derivatives of nitrofurane and medical preparatives containing these compounds | |
| DK0615549T3 (da) | Fremgangsmåde til fremstilling af farmaceutisk aktive thiazolidin- eller oxazolidinforbindelser med en gærreduktase | |
| ATE79257T1 (de) | Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden. | |
| ATE324113T1 (de) | Verwendung von 2,6-dialkyl-4-silyl-phenol derivaten zur behandlung von xanthom | |
| US4094990A (en) | Certain phytofungicidal n-furanyl carbonyl and tetrahydrofuranyl carbonyl, n-(substituted)phenyl alanines | |
| US4483861A (en) | Antihypertensive sulfur-containing compounds | |
| DE69018726D1 (de) | Cumarinderivate, ihre Herstellung und ihre Verwendung zur Behandlung von zerebrovaskulären Störungen. | |
| EP0002978A2 (fr) | Dérivés de thiazolidinedione-2,4, leur préparation et leur application en thérapeutique | |
| BG107051A (en) | Method for the preparation of citalopram | |
| DE69324854D1 (de) | Pyridazinone-Derivate und Verfahren zur deren Herstellung | |
| US5387599A (en) | Triazoles, their production and use | |
| WO2006013049A3 (en) | Benzyloxy derivatives as maob inhibitors | |
| US4822813A (en) | 3-(2-Haloalkyl)-1,4-oxathiins and 2-(2-haloalkyl)-1,4-dithiins, and treatment of leukemia and tumors therewith |